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INTRODUCTION
Glioblastoma represents 15-20% of brain tumors and
50% of all gliomas (1). A characteristic histopathologic
hallmark of glioblastoma is marked cytologic heterogeneity
of astrocytic tumor cells associated with necrosis and/or vas-
cular endothelial proliferation (2, 3). Molecular biologic
studies indicate that glioblastoma is the common end point
in the progression of grade 2 (low-grade) or grade 3
(anaplastic) astrocytomas (4, 5). In the revised WHO classi-
fication of tumors of the central nervous system, glioblas-
toma is classified under the group of astrocytic tumors,
grade 4, as opposed to its prior classification under embry-
onal tumors (6).
Recent clinical and molecular studies indicate the two
different genetic pathways leading to the development of
glioblastomas: (a) final progression of lower grade astrocy-
toma, which arise due to p53 mutation, loss of heterozygosi-
ty (LOH) 17p, amplification of MDM2, CDK4, Rb muta-
tion, LOH 10, and epidermal growth factor receptor
(EGFR) amplification (7-10); and (b) de novo from rapid
malignant transformation of a normal glial cell due to LOH
10 and EGFR amplification (11, 12). Another possible
pathway of glioblastoma development is progression from
other types of gliomas, such as oligodendrogliomas and
oligoastrocytomas by way of genetic lesions of LOH 19q
and 1p (13-15), 9p and 10 (16). Common association of
EGFR amplification and p53 mutation is very rare in the
first pathway (17, 18).
Attempts have been made to link these different molecu-
lar genetic pathways in the development of glioblastomas to
clinical features (17-20). Secondary glioblastomas derived
from lower grade astrocytomas occurs in younger patients
(mean age, 40.5 yr), while de novo glioblastomas tend to
occur in older patients (mean age, 56.3 yr). However, these
studies are primarily based on histopathologic diagnosis of
glioblastomas without clinical distinction between primary
and secondary etiologies.
Kyung Sik Yoon, Min Cheol Lee*, 
Sam Suk Kang, Jae-Hyoo Kim, Shin Jung,
Yoon Ji Kim*, Jae Hyuk Lee*, Kyu Yoon Ahn
� , 
Ji Shin Lee
� , Jong Yoon Cheon
�
Department of Neurosurgery, Pathology* and 
Anatomy
� , Chonnam National University Medical 
School and Research Institute of Medical Sciences,
Kwangju; Department of Pathology
� , College of
Medicine, Seonam University, Kwangju; 
Department of Pathology, College of Natural 
Science
�, Ewha Womans University, Seoul, Korea
Received : 30 October 2000
Accepted : 16 March 2001
Address for correspondence
Min Cheol Lee, M.D.
Department of Pathology, Chonnam National 
University Medical School and Hospital,
5 Hak-dong, Dong-gu, Kwangju 501-190, Korea
Tel : +82.62-220-4300, Fax : +82.62-227-3429
E-mail : mclee@chonnam.ac.kr
*This study was partly supported by the Research
Grants of Chonnam National University in 1997.
481
J Korean Med Sci 2001; 16: 481-8
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
p53 Mutation and Epidermal Growth Factor Receptor Overexpression
in Glioblastoma
Recent molecular studies indicate two different genetic pathways leading to the
development of glioblastoma; final progression of astrocytoma and de novo for-
mation. To define the mutual relationships of cytogenetic changes in the patho-
genesis of glioblastoma, molecular histopathologic alterations of p53 and epi-
dermal growth factor receptor (EGFR) were evaluated by single stranded con-
formational polymorphion, reverse transcriptase-polymerase chain reaction and
immunohistochemical stains in 15 primary and 21 secondary glioblastomas.
Mutations in p53 gene and positive immunoreactivity to p53 protein (DO1) were
more prevalent in secondary glioblastomas than in primary glioblastomas. A cor-
relation between p53 mutations and p53 immunopositivities in glioblastomas
was observed in 83.3% of the cases. All cases with positive p53 immunoreactiv-
ities showed p53 mutations; however, 13.9% of glioblastomas with p53 immuno-
positivities lacked the relevant mutations. EGFR amplifications were detected in
73.3% of primary glioblastomas and 9.5% of secondary glioblastomas (p<0.001).
The concurrence of p53 mutation and EGFR amplification was revealed in only
2 out of 15 primary glioblastomas and none among the secondary glioblastomas.
Immunoreactivities for EGFR were noted in 66.7% of primary glioblastomas and
in 9.5% of secondary glioblastomas (p<0.001). A correlation between EGFR
amplification and EGFR immunopositivity in glioblastomas was observed in 91.7%
of the cases. These data indicate that EGFR amplification and p53 mutations
are two independent genetic events in the development of glioblastomas. 
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The aims of this study are to investigate molecular genet-
ic abnormalities and their correlation to clinical criteria of
primary and secondary glioblastomas and to define the
mutual relationships between p53 mutation and EGFR
amplification.
MATERIALS AND METHODS
Tumor samples
All tumor specimens were obtained from patients under-
going therapeutic operation for brain tumors at Chonnam
National University Hospital from 1993 to 1998. Samples
consisted of fresh-frozen tissues and paraffin-embedded tis-
sue blocks, which were selected based on the adequacy for
the molecular biologic and immunohistochemical studies.
Of the 36 cases, 15 patients had a clinical history of less
than 3 months and were designated as primary glioblas-
tomas. Twenty-one patients had secondary glioblastomas.
Previous operations with initial histopathologic diagnosis of
low grade astrocytomas and anaplastic astrocytomas were
performed in 8 and 13 patients, respectively. The details of
the clinical histories are shown in Table 1 and 2.
Immunohistochemistry for p53 and EGFR proteins
Paraffin-embedded tissue slices, 6  m in thickness, were
immunostained by the avidin-biotin peroxidase (ABC)
method (21). Monoclonal antibodies for DO1 (Santa Cruz,
U.S.A.) and EGFR-NCL (Novocastra, UK) were used at a
titer of 1:100. DO1 binds to both mutant and wild type
p53 proteins, and EGFR-NCL attaches to the extracellular
ligand-binding domain of EGFR (22). The tissue slices
were deparaffinated with xylene. Endogenous peroxidase
activity was quenched by incubation in 0.3% hydrogen
peroxide in 10% methanol. The tissue slices were hydrated
with graded alcohol, treated with 10% normal goat serum
for 30 min, and then incubated with primary antibodies
overnight at a temperature of 4℃ They were incubated
with biotinylated anti-mouse IgG for 30 min at room tem-
perature. The tissue slices for p53 protein immunostaining
were incubated with streptavidin-alkaline phosphatase for
1 hr and developed with fast red TR salt (FRT). EGFR-
labelled tissue slices were incubated with 1% avidin-
biotinylated horseradish peroxidase in 10% normal goat
serum for 1 hr at room temperature and developed in a
mixture of 0.4 mg/mL diaminobenzidine (DAB) in 0.1%
hydrogen peroxide solution for 40 sec. For negative con-
trols, the primary antibodies were omitted in the process of
immunostaining. All immunostained tissues were counter-
stained with hematoxylin solution for 5 min. After dehy-
dration, the tissue was sealed with a universal mount
(Research Genetics, U.S.A.) and examined under a light
microscope. Nuclear staining of p53 was scored semi-quan-
titatively by counting 1,000 cells in the most prominently
stained area of the tissue slides (23). Staining of cell mem-
brane for EGFR was marked as+or - in both low grade and
high grade areas of the tissue slides (24).
SSCP analysis for p53 mutations
DNA was extracted from paraffin sections. For samples
with positive immunostaining with DO1 antibody, the
same areas were chosen for DNA extraction. For samples
with negative immunostaining, DNA was extracted from
Case
number
Age (yr)/
Sex
Site
Gene amplification IHCL IHCH Mutation* IHC-LI (%)
1 54/M P - 0+ + +
2 47/M F - 0+ + +
3 47/M FP - 0 ---
4 53/M F 5/6 3.5 + + +
5 46/M F - 0+ + +
6 39/F TP - 1.8 ±
� --
7 35/M Th 7 2.7 + + +
8 48/M F - 0 ±
� - +
9 68/M O - 0+ + +
10 53/F FP - 0+ - +
11 61/F TP 7 12.3 ---
12 42/F F - 8.1 ---
13 56/M O - 0+ + +
14 55/M TP - 0+ + +
15 49/F F - 0+ --
Table 1. Clinical data and molecular genetic alterations of cases with primary glioblastomas
Sex: M (male), F (female); Site: F (frontal), P (parietal), T (temporal), O (occipital), Th (thalamic)
*: exons, 
� : equivocal amplification interpreted as-(negative) in case 6, + (positive) in case 8
IHC-LI, labeling index by immunohistochemistry; IHCL, immunohistochemistry in low-grade area; IHCH, immunohistochemistry in high-grade area
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the lesion which was histologically typical of a glioblas-
tomas, avoiding the peripheral infiltration zone. Primers for
exons 4-9 of p53 were synthesized (Life Tec, Korea) accord-
ing to published sequences (25). Details of primers are
shown in Table 3. Polymerase chain reaction (PCR)-single
stranded conformational polymorphism (SSCP) analysis was
performed on 50  L of PCR mixture containing PCR reac-
tion buffer (10 mM Tris-HCl, pH 8.8 at 25℃, 1.5 mM
MgCl2, 50 mM KCl, 0.1% Triton X-100), 10 pmol of each
primer, 50  M dNTPs, 3  L template DNA, 1 U DNA
polymerase, and 0.1  Ci  -32P dCTP (NEN, U.S.A.). 
After adding 20  L of mineral oil (Sigma, U.S.A.), 35
cycles were executed. Each cycle consisted of denaturation
(94℃) for 1 min, annealing for 60 sec (58℃ for exons 5/6
and 8/9, and 64℃ for exons 4 and 7), and extension for 2
min (72℃), and was carried out in an automated DNA
Thermal Cycler (Perkin-Elmer, France). Forty microliter of
stop buffer (95% formamide, 10 mM EDTA, 0.05% bro-
mophenol blue and 0.05% xylene cyanol) was added to the
PCR product, and 2  L of the final mixture was sampled.
Samples were heated at 95℃ for 5 min and immediately
loaded onto a 6% non-denaturating polyacrylamide gel
containing 6% glycerol. Gels were run at 30 W for 3 hr,
cooled by fan at room temperature, dried at 60℃, and
autoradiographed for 12-48 hr. 
RT-PCR for EGFR gene amplification
To investigate the expression level of EGFR in human
glioblastoma, we employed a reverse transcriptase (RT)-
PCR assay using EGFR primers. Total RNA was extracted
from the tumor tissues of each glioblastoma patient. After
the reverse transcription, EGFR primers were used for
cDNA amplification. RNA integrity was confirmed with
Case
number
Age (yr)
� /
Sex
Site
Gene amplification IHCL IHCH Mutation* IHC-LI (%)
Secondary glioblastomas developed from low grade astrocytomas
16 27/36/M F 8/9 28.6 ---
17 19/38/M F - 1.5 ---
18 37/40/F FP 7 14.5 ---
19 14/33/F TP - 0+ + +
20 25/34/M F 7 13.6 ---
21 39/45/F O 5/6 7.9 ---
22 21/34/M P 8/9 12.4 ---
23 35/45/M FP 5/6 3.4 ---
Secondary glioblastomas developed from anaplastic astrocytomas
24 53/57/M T 6 30.3 ---
25 39/42/M F - 0 ---
26 41/46/M FP - 6.5 ---
27 27/34/F F 7 7.3 ---
28 68/72/M P - 8.7 ---
29 41/43/M PO 8/9 10.5 ---
30 44/47/F T - 0 ---
31 50/55/F F - 0+ - +
32 36/40/F F 7 1.7 ---
33 23/28/M FP 8/9 13.9 ---
34 19/27/F O 7 2.6 ---
35 33/38/M F - 5.7 ---
36 33/37/F TO 6 14.9 ---
Table 2. Clinical data and molecular genetic alterations of cases with secondary glioblastomas
*, exons; 
� , age at the first biopsy of astrocytomas
Sex: M (male), F (female); Site: F (frontal), P (parietal), T (temporal), O (occipital)
IHC-LI, labeling index by immunohistochemistry; IHCL, immunohistochemistry in low-grade area; IHCH, immunohistochemistry in high-grade area
p53 EGFR
4 ATC-TAC-AGT-CCC-CCT-TGC-CG GCA-ACT-GAC-CGT-GCA-AGT-CA
5/6 TC-CTC-TTC-CTG-CAG-TAC-TC AGT-TGC-AAA-CCA-GAC-CTC-AG
7 GTG-TTG-CCT-CCT-AGG-TTG-GC CAA-GTG-GCT-CCT-GAC-CTG-GA
8/9 CCT-ATC-CTG-AGT-AGT-GGT-AT CCA-AGA-CTT-AGT-ACC-TGA-AG
Table 3. The oligonucleotide primers used to amplify exons 4-9 of p53 gene in polymerase chain reaction (5'-3')
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parallel RT-PCR amplification using  -actin primers. PCR
products were electrophoresed on agarose gels containing
ethidium bromide and visualized by UV photography. The
detailed procedure was as follows. 
Total RNA was extracted from frozen tissues using the
LiCl/Urea method (26). For cDNA synthesis, 3  g of total
RNA was annealed to oligo (dT) 15 in 20  L total volume
containing 4  L of 5 XM-MLV RT buffer (50 mM Tris-
HCl, pH 8.3, 7.5 mM KCl, 3 mM MgCl2, and 10 mM
DTT), 0.5 mM dNTP, 20 U RNase and 200 U M-MLV
RT (Promega, Germany) and was incubated at 37℃ for 1.5
hr. PCR mixture contained 1X PCR buffer (50 mM KCl,
10 mM Tris-HCl, pH 9.0, and 0.1% Triton X-100), 1 mM
MgCl2, 0.2  M of each primer, 0.2 mM dNTP, 2.5 U of
Taq DNA polymerase (Promega, Germany) and 1.5  g of
cDNA in a final volume of 50  L. The amplification was
performed in the DNA Thermal Cycler. Twenty-five PCR
cycles were performed which consisted of 1 min at each
temperature (94℃, 53℃, 72℃), except for the initial
cycle (5 min at 94℃) and the final extension step (5 min at
72℃). Primer sequences for EGFR and  -actin (reference
gene) were as follows: 5′ -AGCCATGCCCGCATTAGCTC-
3′ (5′ primer) and 5′ -AAAGGAATGCAACTTCCCAA-3′
(3′ primer) for EGFR (24) resulting in a 110-bp PCR prod-
uct, 5′ -GACTATGACTTAGTTGCGTTA-3′ (5′ primer)
and 5′ -GCCTTCATACATCTCAAGTTG-3′ (3′ primer)
for  -actin resulting in a 501-bp PCR product. 
Statistical Analysis
All statistical analysis was performed using Statistical
Package for the Social Sciences (SPSS/PC+7.5, Chicago,
IL, U.S.A.). A p value of less than 0.05 was accepted as sta-
tistically significant. The Student t-test was used to evalu-
ate differences in the age of patients and p53 labeling index
(LI) between primary and secondary glioblastomas. The chi-
square and Fisher’ s exact tests were used to analyze differ-
ences in sex ratio, p53 mutations, p53 expression, EGFR
amplification, and EGFR expression. 
RESULTS
The results of this study are summarized in Table 4. The
mean ages of the patients with primary and secondary
glioblastomas at the time of surgery were 50.2±8.4 yr and
41.5±10.4 yr respectively. The mean age of the patients
with primary glioblastomas was significantly higher than
that with secondary glioblastomas. The frequencies of both
primary and secondary glioblastoma were higher in males
than in females but the difference was not statistically sig-
nificant.
p53 mutations were detected in 3 out of 15 (20.0%) pri-
mary glioblastomas (Fig. 1) and in 13 out of 21 (61.9%)
secondary glioblastomas (p=0.014). All mutations were
located between exons 5 to 9. Immunoreactivity to the p53
gene product was expressed on nuclei of glioblastoma cells.
The distribution of p53-positive cells was very heteroge-
nous in many cases (Fig. 2), and there was no specific rela-
1353
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Fig. 1. Presence of exon 7 DNA of the p53 gene in glioblastomas
by PCR (A), and mutations (*) revealed by single stranded con-
formational polymorphism (Lane 1-11; secondary glioblastoma
cases).
Age at first biopsy (yr) 50.2±8.4* 34.5±12.9* 0.000 (1)
Age at glioblastoma biopsy (yr) 50.2±8.4* 41.5±10.4* 0.009 (1)
Sex ratio (M/F) 10/5(2.0) 12/9 (1.3) 0.411 (2)
p53 mutation (SSCP) 20.0% 61.9% 0.014 (2)
P53 expression (IHC) 33.3% 81.0% 0.001 (2)
P53 labeling index
� 5.7±4.4%* 10.8±8.3%* 0.002 (1)
EGFR amplification (RT-PCR) 73.3% 9.5% 0.000 (2)
EGFR expression (IHC) 66.7% 9.5% 0.001 (2)
p53 mutation and EGFR amplification 13.3% 0.0% 0.000 (2)
Table 4. Summary of clinical data and molecular genetic alterations in 36 patients with glioblastomas
Primary glioblastoma (n=15) Secondary glioblastoma (n=21) p value (Method)
n, number of cases; *, Mean±Standard deviation (S.D.); 
� , Mean±S.D in P53-positive cases
SSCP, single stranded conformational polymorphiom; RT-PCR, reverse transcriptase polymerase chain reaction; IHC, immunohistochemistry; EGFR,
epidermal growth factor receptor; (1), Student t-test; (2), chi-square test and Fisher’ s exact testCytogenetic Changes in Glioblastoma 485
tionship between p53 immunoreactivity and nuclear mor-
phology. Immunoreactivity to DO1 was observed in 5 out
of 15 (33.3%) primary glioblastomas, and in 17 out of 21
(81.0%) secondary glioblastomas (p=0.001). The mean p53
labeling index (LI) was 5.7±4.4 % and 10.8±8.3 % in
primary and secondary glioblastomas, respectively (p=0.002).
The correlative results between p53 mutations and p53
immunoreactivities were observed in 30 out of 36 (83.3%)
glioblastomas (both positive, 44.4%; both negative, 38.9%).
p53 labeling index mutations were observed in all p53-posi-
tive glioblastomas; however, 5 out of 36 (13.9%) glioblas-
tomas revealed p53-immunopositivities without p53 muta-
tions.
There were two cases with equivocal amplifications of
EGFR by RT-PCR. One showed EGFR-positive immuno-
reactivity and the other was negative. Among the two, the
one with positive immunoreactivity to EGFR was consid-
ered as positive EGFR amplification. EGFR amplifications
were detected in 11 out of 15 (73.3%) primary glioblas-
tomas and 2 out of 21 (9.5%) secondary glioblastomas
(p<0.001). The concurrence of p53 mutation and EGFR
amplification was observed only in 2 among 15 primary glio-
blastomas (Table 1), and even absent in secondary glioblas-
tomas (Table 2). EGFR immunoreactivity was noted along
the cell membrane of glioblastoma cells (Fig. 3). Immuno-
reactivity for EGFR was noted in 10 out of 15 (66.7%) pri-
mary glioblastomas, and in 2 out of 21 (9.5%) in secondary
glioblastomas (p<0.001). The correlative results between
EGFR amplification by RT-PCR and EGFR immunoreac-
tivity was observed in 33 out of 36 (91.7%) glioblastomas
(both positive, 30.6%; both negative, 61.1%). Only one
case revealed EGFR amplification without EGFR-positive
glioblastoma cells. Among the 12 immunopositive cases,
nine (75.0%) showed immunoreactivities in both low and
high grade areas of glioblastomas while three (25.0%) showed
only in high grade areas.
DISCUSSION
The recent molecular biologic studies of astrocytic tumors
suggest that both activation of oncogenes and inactivation
of tumor suppressor genes are involved in the development
of glioblastomas. Von Deimling et al. indicated that there
were two types of glioblastomas based on their molecular
biologic pathogenesis (27). The type 1 (secondary) glioblas-
toma occurs with LOH on chromosome 17p closely associ-
ated with p53 mutations and is more common in younger
patients. The type 2 (primary) glioblastoma is characterized
by higher frequencies of EGFR amplification and LOH on
chromosome 10, and is common in elderly patients. The
molecular features of primary and secondary glioblastomas
were shown to be strongly correlated with the patients’
clinical history in the recent studies (19, 27, 28).
Although some studies support the classification of
glioblastomas into two subtypes, only a few studies have
analyzed molecular genetic alterations of EGFR and p53 in
association with immunohistochemical findings on tumor
samples. According to our results, the mutations of the p53
gene were found in 20.0% of primary glioblastomas and
61.9% of secondary glioblastomas. This observation is con-
sistent with the high rate of p53 mutations reported by
Watanabe et al. (29). The high rate of p53 mutation in sec-
ondary glioblastomas might be due to the selection of biop-
sies according to the definite evidence of clinical progres-
sion from low grade or anaplastic astrocytomas. p53 protein
immunoreactivity was noted in 33.3% and 80.1% of pri-
mary and secondary glioblastomas, respectively. In the pres-
ence of p53 gene mutations, positive staining of tumor cells
for p53 protein might be expected; however, correlative
studies of p53 protein immunohistochemistry and p53 gene
mutation in glioblastomas reported a higher rate of protein
expression than the gene mutation (30, 31). The results of
this study suggest that an alternative mechanism of p53
gene mutation can result in p53 protein accumulation. In
this study, p53 LI was scored 5.7±4.4% and 10.8±8.3%
in primary and secondary glioblastomas, respectively. There
has been reported a wide range of nuclear staining of p53 in
glioblastomas (23, 29), and the difference might be
attributed to the divergent monoclonal antibodies or to the
scoring system used in each study. 
EGFR is a member of the tyrosine kinase family of cell
surface receptors and demonstrates various levels of expres-
sion throughout the cellular development and in a variety of
different cell types. The receptor can transduce signals into
the cells upon: 1) interaction with ligands such as EGF,
1 2 3 4 5 6 7 8 9 1 01 11 21 3
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Fig. 2. EGFR amplification detected by reverse transcriptase
polymerase chain reaction in a control brain (lane 1), glioblas-
tomas (lanes 2-12), and negative control (lane 13). Note regular
500bp bands of  -actin mRNA as a positive control.
110bp
500bp
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transforming growth factor (TGF- ), amphiregulin or hep-
arin-binding EGF; 2)  truncation or mutation of extracellu-
lar and/or intracellular domains; and 3) amplification of a
basal receptor activity in the absence of ligand through
cooperation with other cellular signaling pathways or nucle-
ar events, such as an expression of v-erbB (32, 33). EGFR
has been implicated in human cancers, where it may con-
tribute both to the initiation (glioblastoma) and progression
(epithelial tumors) of the disease. It is frequently present in
an amplified or over-expressed form in up to 30-40% of
malignant gliomas (34, 35).
According to the present study, the incidence of EGFR
amplification was 73.3% and 9.5% in primary and sec-
ondary glioblastomas, respectively. Recent studies on EGFR
amplification in glioblastoma were carried out by sub-
grouping as primary and secondary forms. Lang et al. (36)
reported 5 cases out of 34 glioblastomas had EGFR amplifi-
cation and LOH on chromosome 10 without p53 muta-
tions. Watanabe et al. (29) demonstrated a 63% incidence
of EGFR amplification in primary glioblastomas compared
to that of only 10% in secondary glioblastomas. According
to the present study, positive immunohistochemical stain-
C D
A B
Fig. 3. EGFR immunohistochemistry revealed strong positivity on cell membrane of primary glioblastomas (A; high grade area, B; low
grade area) and no immunoreactivity in high grade area (C) in a single case. Similar immunoreactivities are noted in a few cases of sec-
ondary glioblastoma (D) (A,B,D×100, C×90).Cytogenetic Changes in Glioblastoma 487
ings for EGFR were observed in 66.7% and 9.5% of prima-
ry and secondary glioblastomas, respectively. Correlative
studies between EGFR gene amplification and immunohis-
tochemical finding are rare. A comparative study by Rieske
et al. (37) reported 13 cases (45%) with immunopositivity
for EGFR in a series of 28 glioblastomas, while amplifica-
tion of EGFR gene was observed in 12 cases. In this study,
only one case showed no EGFR immunoreactivity in the
presence of EGFR gene amplification, and two cases demon-
strated weak EGFR immunoreactivity without EGFR gene
amplification. There seems to be no strict correlations bet-
ween EGFR gene amplification and the protein overexpres-
sion. EGFR was relatively well expressed in both low grade
and high grade areas of glioblastomas, despite a few excep-
tional cases. Three out of 12 EGFR immunopositive cases
were not stained in low grade areas. Concerning with the
morphological heterogeneity of glioblastoma, the other
study (38) reported that genetic abnormalities seen in the
low grade areas were conserved in the high grade areas sug-
gesting that these morphologically different cellular subsets
were derived from a common transformed clone. These fin-
dings might be helpful to detect the presence or absence of
tumor cell infiltrations in the peripheral margin or edema-
tous area of glioblastomas.
In this study, the p53 mutation with concomitant EGFR
gene amplification was observed in 13.3% of primary
glioblastoma. There were no such cases among secondary
glioblastomas. In line with this observation, Watanabe et
al. reported only one case with such profile out of 20 sec-
ondary glioblastomas and none in 19 primary glioblastomas
(29). These data indicate that EGFR amplification and p53
mutation are two different genetic events in the develop-
ment of glioblastomas. 
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